Summary of Contineum Therapeutics Conference Call Company Overview - **Company**: Contineum Therapeutics (NasdaqGS:CTNM) - **Focus**: Small molecule drug development in neuroscience, inflammation, and immunology, particularly targeting pulmonary fibrosis [3][4] Core Strategic Focus - Transitioned from a platform-based drug discovery model to a company with two clinical-stage assets: PIPE-791 and PIPE-307 [3] - PIPE-791 is a best-in-class inhibitor of the LPA1 receptor, with two key clinical trials planned for 2026 [3][4] - PIPE-307 is a first-in-class brain-penetrant M1 receptor inhibitor, partnered with Johnson & Johnson, currently in a Phase 2 study for major depressive disorder (MDD) [4][28] Clinical Trials and Data PIPE-791 - **Clinical Trials**: Three ongoing trials, including an exploratory study in chronic pain and a Phase 2 study in idiopathic pulmonary fibrosis (IPF) [3][4] - **Differentiators**: - Achieves 90% receptor occupancy at a low dose of 1 mg daily, compared to BMS's higher dose requirement [8][10] - No hypotension signal observed in studies, unlike BMS's compound [8][18] - Designed for convenience with a once-daily dosing regimen [10][27] - **Phase 2 Study Design**: 108 subjects, three arms (placebo and two doses), 26-week duration, allowing background therapy [11][12] PIPE-307 - **Study Focus**: MDD with a primary efficacy endpoint of change in MADRS on day five [29] - **Partnership Economics**: $50 million upfront from J&J, over $1 billion in milestones, and royalties starting in the low teens, potentially reaching 20% [35] Market Position and Competitive Dynamics - Contineum aims to position PIPE-791 as a backbone therapy for IPF, with potential for combination therapies [25][27] - The company believes it has a best-in-class approach, differentiating itself from competitors like BMS [25][27] Upcoming Catalysts - **Key Data Events**: - Results from the BMS Phase 3 trial expected in Q4 2026, which could validate the LPA1 target [20][57] - Readout from the MDD study (MOONLIGHT 1) anticipated in late summer or early fall [57] - Results from the chronic pain exploratory study, although not a primary investment thesis [37][57] Key Opinion Leader (KOL) Feedback - Positive feedback on the LPA1 mechanism, with enthusiasm for the once-daily dosing and tolerability profile [51][52] - Clinical validation from BMS's data is seen as a strong indicator of potential success for Contineum's programs [53] Financial Position - The company is well-funded through mid-2029, with no immediate financial obligations for PIPE-307 due to J&J's support [47] Conclusion - Contineum Therapeutics is positioned to leverage its clinical assets PIPE-791 and PIPE-307 in the competitive landscape of pulmonary fibrosis and major depressive disorder, with several key data readouts expected to drive investor interest and validate its strategic direction [53][57]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-42001 Contineum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1467257 Sta ...

Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES - Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 SAN DIEGO – March 5, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company ...

Company Overview - Contineum Therapeutics, Inc. (CTNM) is part of the Medical group, which consists of 928 companies and is currently ranked 10 in the Zacks Sector Rank [2] - CTNM has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for CTNM's full-year earnings has increased by 11.5%, reflecting improved analyst sentiment [4] - Year-to-date, CTNM has achieved a return of approximately 33.1%, significantly outperforming the average return of 3.5% for Medical companies [4] Industry Comparison - CTNM belongs to the Medical - Biomedical and Genetics industry, which includes 449 stocks and is currently ranked 90 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has seen an average gain of 19.4% this year, indicating that CTNM is performing well within its specific industry [6] Additional Comparisons - Another Medical stock, Quest Diagnostics (DGX), has returned 6.7% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Quest Diagnostics is part of the Medical - Outpatient and Home Healthcare industry, which has a lower year-to-date return of 3.6% and is ranked 196 [7]

Core Viewpoint - Contineum Therapeutics, Inc. (CTNM) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Company Performance Indicators - The Zacks Consensus Estimate for Contineum Therapeutics has increased by 8.8% over the past three months, with an expected earnings per share of -$2.18 for the fiscal year ending December 2025, showing no year-over-year change [8]. - The upgrade to Zacks Rank 2 places Contineum in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. Zacks Rating System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, maintaining a balanced distribution of ratings across over 4,000 stocks [7][9]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, highlighting the effectiveness of the rating system [7].

Core Viewpoint - Contineum Therapeutics, Inc. (CTNM) shows significant upside potential with a mean price target of $21.83, indicating a 91.5% increase from the current trading price of $11.4 [1] Price Targets - The average price target consists of six estimates ranging from a low of $14.00 to a high of $29.00, with a standard deviation of $4.79, suggesting variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 22.8%, while the highest suggests a 154.4% upside [2] Analyst Sentiment - Analysts are optimistic about CTNM's earnings prospects, with a consensus indicating better earnings than previously estimated, which historically correlates with stock price increases [4][11] - The Zacks Consensus Estimate for the current year has increased by 1.6% due to one upward revision in estimates over the last 30 days [12] Zacks Rank - CTNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Insights - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movements [14]

Core Viewpoint - Contineum Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of its Class A common stock at $12.25 per share, indicating a strategic move to raise capital for its clinical-stage biopharmaceutical initiatives [1] Company Summary - The company is focused on developing differentiated therapies targeting neuroscience, inflammation, and immunology (NI&I) indications, highlighting its commitment to advancing treatment options in these critical areas [1] - The public offering consists of 7,346,938 shares, which reflects an increase in the size of the offering, suggesting strong investor interest and confidence in the company's future prospects [1] - Contineum has provided underwriters with a 30-day option, which may allow for additional shares to be sold, further indicating the company's proactive approach to capitalizing on market conditions [1]

Summary of Contineum Therapeutics FY Conference Call Company Overview - **Company**: Contineum Therapeutics (NasdaqGS:CTNM) - **Focus**: Clinical studies and drug development, particularly in the areas of idiopathic pulmonary fibrosis (IPF), chronic pain, and multiple sclerosis (MS) Key Accomplishments - **First Full Year as a Public Company**: Successfully executed four clinical studies in 2025 [2][3] - **PIPE-791**: Completed a phase 1b PET receptor occupancy study, validating dose selections for a phase 2 study in IPF [3][4] - **Phase 1b Exploratory Study**: Fully enrolled in chronic pain, results expected in the first half of the upcoming year [3][4] - **PIPE-307**: Reported VISTA data, although the primary endpoint was missed, the study was well-controlled [4] Clinical Studies and Drug Development - **PIPE-791**: Targeting LPA1 receptor antagonism for IPF and chronic pain, with a phase 2 study set to begin [4][5] - **Mechanism of Action**: LPA1 receptor activation leads to fibroblast recruitment and collagen secretion, contributing to fibrosis and chronic lung disease [5][6] - **Chronic Pain Program**: Focus on LPA1's role in pain pathways, with plans for studies in osteoarthritis and chronic lower back pain [20][21] Market Landscape and Competitive Positioning - **Current IPF Treatments**: Three approved drugs (pirfenidone, nintedanib) have significant tolerability issues, leading to high patient dropout rates [9][10] - **Market Opportunity**: Approximately 130,000 patients with IPF in the U.S. present an untapped market, with existing drugs generating over $4 billion in sales despite their drawbacks [17] - **Differentiation from Competitors**: Contineum's LPA1 antagonist is expected to have a once-daily dosing regimen, higher receptor occupancy, and potentially better safety and tolerability compared to Bristol's LPA1 antagonist [11][12] Regulatory Pathway - **Phase 2 Study Design**: 26-week study with primary endpoint focused on change in forced vital capacity [13] - **Future Studies**: Anticipation of two phase 3 studies for regulatory approval in IPF and PPF [15] Challenges and Considerations - **Recruitment Difficulties**: IPF studies are challenging due to patient frailty and logistical issues [19] - **Exploratory Nature of Pain Studies**: The chronic pain study is small and not powered, with a focus on identifying trends rather than definitive outcomes [21] Future Catalysts - **Upcoming Data Releases**: Top-line data from the chronic pain study expected in the first half of the year, and BMS's phase 3 data anticipated in the fourth quarter [24] Additional Insights - **Research Findings**: Data from human fibroblasts and donor slices indicate increased LPA1 expression in IPF tissue, supporting the rationale for targeting this receptor [16] - **Safety and Tolerability**: Consistent safety profile observed in previous studies, with no significant hypotension signals noted [12][22] This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic direction, clinical focus, and market positioning.

Core Viewpoint - Contineum Therapeutics, Inc. is participating in the 8th Annual Evercore Healthcare Conference, indicating its active engagement in the healthcare sector and potential interest from investors [1] Company Participation - Management of Contineum Therapeutics is scheduled for a fireside chat at the conference on December 3, 2025, at 1:20 p.m. ET, showcasing the company's commitment to communicating with stakeholders [1] - An audio webcast of the fireside chat will be available, providing broader access to the company's insights and updates [1]

Core Insights - Contineum Therapeutics, Inc. reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS) [1] - The trial showed acceptable safety and tolerability but did not meet its primary or secondary efficacy endpoints [2] - The company plans to present the complete dataset at a future medical meeting and publish full results in a peer-reviewed journal [3] Trial Results - The trial did not show significant changes in binocular 2.5% low contrast letter acuity across treatment arms in RRMS patients [2] - RBC Capital Markets noted that the trial was high risk compared to other programs due to limited evidence, despite some preclinical rationale [4] Future Plans - The company initiated a global Phase 2 clinical trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) in Q4 2025 [5] - The initiation of PIPE-791 PrMS and CTX-343 clinical development efforts has been deferred, extending the projected cash runway through 2028 [5] Market Reaction - Following the trial results, CTNM stock decreased by 13.26%, trading at $10.60 [6]